The potential $725 million acquisition of Ipierian Inc. by Bristol-Myers Squibb Co. (BMS) merited less than two minutes in the big pharma's first quarter earnings call Tuesday morning and garnered only a single question from analysts. Still, the deal for the San Francisco-based biotech raised tantalizing questions about the direction of its tau program in the hands of a pharma better known for cardiovascular and oncology drug development.